Dear Ms
Thank you very much for this information which we will consider in our work.
Kind regards,
Hala
Hala Audi
Head of the Review Team
Gibbs Building, 215 Euston Road, London NW1 2BE
T +44 (0)20 7611 5709 M +44 (0)7715 426891
T +44 (0)20 7611 5709 M +44 (0)7715 426891
From: Jim O'Neill [mailto:jim@o-neilluk.com]
Sent: 22 May 2015 08:50
To: Audi, Hala
Subject: FW: Please forward to Jim o neill
Sent: 22 May 2015 08:50
To: Audi, Hala
Subject: FW: Please forward to Jim o neill
From: Áine Quinn [mailto:aine.quinn@bruegel.org]
Sent: 22 May 2015 08:48
To: Vikki Stewart; Jim O'Neill
Subject: Fwd: Please forward to Jim o neill
Sent: 22 May 2015 08:48
To: Vikki Stewart; Jim O'Neill
Subject: Fwd: Please forward to Jim o neill
---------- Forwarded message ----------
From:
Date: Fri, May 15, 2015 at 6:09 AM
Subject: Please forward to Jim o neill
To: "aine.quinn@bruegel.org" <aine.quinn@bruegel.org>
Dear Jim o neill,
I coo mend to your attention the work of Denise l faustman, pubmed.org faustman DL,faustmanlab.org, and pubmed.org RISTORI Bcg.
Not only is Bcg defective in reducing the likelihood of contracting multi drug resistant tb but it is useful for treating autoimmune diseases.
The previous defects in using tb aerosol as a weapon had now been somewhat overcome with the advent of multi drug resistant tb.
I have triedbcg for my plaque psoriasis with good results.
I would like to demonstrate same on you tube.
It will require more work to optimize the dose and scheme for my diabetes.
It is sad when good work like faustman's is not quickly and widely applied.
It sometimes seems as if drug companies look forward to the race
Between weaponized aerosol multidrug resistant tb and anything they may sell .
Bcg should be widely and inexpensively available in the us.
Sadly it is not.
I look forward to your thoughts on an old defense against multidrug resistant tb that has so many other and better uses.
Sincerely yours
From:
Date: Fri, May 15, 2015 at 6:09 AM
Subject: Please forward to Jim o neill
To: "aine.quinn@bruegel.org" <aine.quinn@bruegel.org>
Dear Jim o neill,
I coo mend to your attention the work of Denise l faustman, pubmed.org faustman DL,faustmanlab.org, and pubmed.org RISTORI Bcg.
Not only is Bcg defective in reducing the likelihood of contracting multi drug resistant tb but it is useful for treating autoimmune diseases.
The previous defects in using tb aerosol as a weapon had now been somewhat overcome with the advent of multi drug resistant tb.
I have triedbcg for my plaque psoriasis with good results.
I would like to demonstrate same on you tube.
It will require more work to optimize the dose and scheme for my diabetes.
It is sad when good work like faustman's is not quickly and widely applied.
It sometimes seems as if drug companies look forward to the race
Between weaponized aerosol multidrug resistant tb and anything they may sell .
Bcg should be widely and inexpensively available in the us.
Sadly it is not.
I look forward to your thoughts on an old defense against multidrug resistant tb that has so many other and better uses.
Sincerely yours
--
 |
This message has been scanned for viruses by Websense Hosted Email Security
No comments:
Post a Comment